Clinical Trial Update: Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PCI-32765 (acalabrutinib) in combination with obinutuzumab for untreated indolent non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)
• PCI-32765 (ibrutinib)

Snippet

Sponsor: Ludwig-Maximilians - University of Munich | Conditions: Indolent Non-Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN